

# Early childhood respiratory morbidity and antibiotic use in ex-preterm infants: A primary care population-based cohort study

Shin Tan<sup>1</sup>, Lisa Szatkowski<sup>2</sup>, William Moreton<sup>1</sup>, Linda Fiaschi<sup>2</sup>, Tricia McKeever<sup>2</sup>,  
Jack Gibson<sup>2</sup>, Don Sharkey<sup>1</sup>

## Affiliations:

<sup>1</sup>Academic Child Health, School of Medicine, University of Nottingham, Nottingham, UK;

<sup>2</sup>Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK

## Address correspondence to:

Dr Don Sharkey, Associate Professor of Neonatal Medicine,  
Academic Child Health, E floor, East Block, University Hospital, Nottingham, NG7 2UH,  
UK.

Email don.sharkey@nottingham.ac.uk Tel: +44 115 823 0602 Fax: +44 115 823 0626

**Keywords:** bronchopulmonary dysplasia, chronic neonatal lung disease, respiratory infection, wheeze, antibiotic treatment, preterm

**Key message:** Our English population-based cohort study in early childhood highlights the significant respiratory morbidity, antibiotic use and increased primary healthcare utilisation in ex-preterm infants, particularly those who were discharged home in oxygen.

**Authors' Contributions:** DS and LS designed the study. LS and LF provided data and undertook data linkage. ST built the final dataset for the study. ST and WM undertook the statistical analyses under supervision of LF, TM and JG. All authors interpreted the results. ST drafted the manuscript, and all other authors contributed revisions.

**Funding:** No funding received

## **Abstract**

**Background:** Globally, bronchopulmonary dysplasia (BPD) continues to increase in preterm infants. Recent studies exploring subsequent early childhood respiratory morbidity have been small or focused on hospital admissions.

**Primary aim:** Examine early childhood rates of primary care consultations for respiratory tract infections (RTI), lower respiratory tract infections (LRTI), wheeze and antibiotic prescriptions (Abx Px) in ex-preterm and term children. **Secondary aim:** examine differences between preterm infants discharged home with or without oxygen.

**Methods:** Retrospective cohort study using linked electronic primary care and hospital databases of children born between 1997 to 2014. We included 253,277 eligible children, with 1,666 born preterm <32 weeks' gestation, followed up from primary care registration to age 5 years. Adjusted incidence rate ratios (aIRR) were calculated.

**Results:** Ex-preterm infants had higher rates of morbidity across all respiratory outcomes. After adjusting for confounders, aIRRs for RTI (1.37, 95% CI 1.33-1.42), LRTI (2.79, 95% CI 2.59-3.01), wheeze (3.05, 95% CI 2.64-3.52) and Abx Px (1.49, 95% CI 1.44-1.55) were higher for ex-preterm infants. Ex-preterm infants discharged home on oxygen had significantly greater morbidity across all respiratory diagnoses and Abx Px compared to those without home oxygen. The highest rates of respiratory morbidity were observed in children from the most deprived socioeconomic groups.

**Conclusion:** Ex-preterm infants, particularly those with BPD requiring home oxygen, have significant respiratory morbidity and antibiotic prescriptions in early childhood. With the increasing prevalence of BPD, further research should focus on strategies to reduce the burden of respiratory morbidity in these high-risk infants after hospital discharge.

## **Introduction**

Survival of preterm, very low birth weight (VLBW) infants has improved with the introduction of antenatal corticosteroids, surfactant administration, along with better nutrition and ventilation strategies [1–4]. However, the incidence of bronchopulmonary dysplasia (BPD), a chronic respiratory condition of prematurity, continues to increase and is a major cause of long-term morbidity and mortality in preterm survivors [5–7]. In Europe, the prevalence of BPD in infants born before 32 weeks gestational age (GA) has increased from 23.3% (2007-11) to 27.5% (2012-15) [8], equating to approximately 28,000 affected preterm infants annually based on current birth rates [9]. In the USA, current annual estimates of new cases of BPD range between 10,000-15,000 [10, 11].

BPD is associated with long-term adult respiratory morbidity, including asthma and chronic obstructive pulmonary disease [3, 12, 13]. In the UK, guidance on post-discharge follow-up for respiratory management in preterm infants with BPD is only provided for those requiring home oxygen, omitting a larger group with less severe BPD [14]. Moreover, there is need to explore additional periods in early life which are potentially amenable to alterations of the adverse respiratory trajectory and hence reduce long-term morbidities. One potential roadblock to achieving these goals is the lack of recent, nationally representative data on early childhood respiratory morbidity in preterm survivors outside of the hospital setting. Greenough and colleagues studied ex-preterm infants and provided many useful insights into their respiratory health [15]. However, this small study of infants born in 1994-97 did not provide respiratory diagnoses or antibiotic use, had no term comparison group and follow-up stopped at two years of age. A larger, more contemporary study with a term comparator group may provide important information on the respiratory outcomes of these children and identify disparities to be further explored in future research [16][17].

We hypothesised that ex-preterm infants have increased respiratory morbidity in early childhood. The primary aim of our study was to quantify early childhood respiratory morbidity in preterm survivors compared to their term-born counterparts. The secondary aims were to examine differences between preterm infants discharged home with or without oxygen.

## **Methods**

### **Data source**

This is a retrospective cohort study, using data obtained from the Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics (HES). CPRD is a large, representative national primary

care dataset containing anonymised medical records currently encompassing 42 million patient lives from over 1,700 primary care practices in the UK [18]. Information is routinely and prospectively recorded for each patient, including patient demographic information, details of consultations, tests and diagnoses, and medical prescriptions. HES is a database containing information on all admissions to NHS hospitals in England [19]. Clinical information relating to diagnoses and procedures are recorded using codes from the International Classification of Diseases, 10th revision (ICD-10) and UK Office of Population, Census and Surveys (OPCS) Classification of Interventions and Procedures version 4.6, respectively [20, 21]. Approximately 75% of active practices contributing to CPRD in England (58% of all UK practices) are linked with HES, thus providing additional secondary care clinical information for all patients from these practices [22]. We used linked HES data to improve the quality and accuracy of our data as information such as an infant's birth weight and gestational age are often included in the mother's hospital records. Both databases have been validated with other sources of information and are widely used for epidemiological research [22].

### **Study population and exposure groups**

We included children born in English hospitals from April 1997 to May 2014 who were registered with a CPRD practice within six months of birth and had at least three months of follow-up data (Figure 1). They were followed up from first registration in CPRD until either their fifth birthday, 31 December 2014 (database extraction date) or when they left the general practice. We included all infants with a GA of 23+0 weeks to 43+6 weeks and with sex-specific birth weights from the 9<sup>th</sup> to 91<sup>st</sup> centiles were included (94.9%) [23]. This avoided any erroneous entries with birth weight and the majority with abnormal growth patterns, as identification of babies with growth restriction was not possible from this dataset. The distribution of our study population was broadly similar to the population distribution for gestational age and birth weight released by the Office of National Statistics 2010 (Supplementary tables 1 and 2), considering CPRD underrepresents babies born at the extreme of prematurity as it includes only survivors who register with a general practice, whereas ONS data include all registered live births.

For our primary analysis, we identified two cohorts of newborn infants: 1) term infants born  $\geq 37$  completed weeks of gestation, with birth weights  $\geq 2500$ g and without prescriptions for home oxygen (Term); and 2) preterm infants born before 32 completed weeks of gestation with birth weights  $< 1500$ g (Preterm). The Preterm group were further divided into two cohorts for secondary sub-group analysis: those with (PT-O<sub>2</sub>) and without (PT-Air) home oxygen prescriptions in their medical records within three months of registration at their general practice.

## **Outcome variables**

The primary outcomes were defined as a) rates of primary care consultations for three respiratory conditions - respiratory tract infection (RTI, including both upper and lower RTIs), lower respiratory tract infection specifically (LRTI), and wheeze; and b) rates of antibiotic prescriptions (Abx Px).

Episodes of respiratory outcomes were identified using Read medical codes recorded in primary care records (available from the authors on request) [24, 25]. For example, an RTI was defined based on a recorded clinical diagnosis of a relevant infection (e.g. acute respiratory infection, acute pharyngitis) or an infection-related symptom (e.g. cough with fever, sore throat) during the follow-up period. As previously, we defined recovery as the 15<sup>th</sup> day after the initial diagnosis of infection [24, 25] with any subsequent diagnosis considered to be the same infection episode and the recovery date was extended to the 8<sup>th</sup> day of this recording (if later than original recovery date), to ensure each episode lasted at least 14 days.

Antibiotic prescriptions were identified using Multilex drug codes (drug codes available from the authors on request). We included antibiotics detailed as suitable for treating respiratory infections, as defined by the British National Formulary for Children (BNFC) in the following classes: penicillins; cephalosporins and other beta-lactams; macrolides; and sulphonamides and trimethoprim [26].

## **Other co-variables**

Data were extracted on descriptive characteristics and co-variables including sex, socioeconomic status measured using the Index of Multiple Deprivation (IMD) 2010 [27, 28], and presence of major congenital anomalies based on the European Surveillance of Congenital Anomalies (EUROCAT) definition [29]. Outcomes were quantified based on yearly age bands from birth to five years.

## **Statistical analyses**

Data management and analyses were undertaken using STATA version 14 (StataCorp, College Station, TX, USA). The number of episodes of respiratory infection, antibiotic prescriptions and crude incidence rate (IR) per 10 person years with 95% confidence intervals (95% CI) were calculated both overall and separately for each covariable. We used negative binomial regression to generate incidence rate ratios (IRR) comparing preterm to term infants with adjustment for potential confounders, including yearly age bands, sex, IMD 2010 quintiles and presence of congenital anomalies.

To examine the differences in outcomes between ex-preterm infants discharged home in air (PT-Air) and ex-preterm infants discharged on home oxygen (PT-O<sub>2</sub>), we repeated the above steps as further sub-group analyses and compared these results to their term counterparts.

In addition, we conducted the analyses over two epochs to assess changes in respiratory morbidity over time. We divided the study period into two equal 8-year epochs: Epoch 1 (1997-2005) and Epoch 2 (2006-2014).

## **Ethical approval**

The providers of the CPRD data received ethical approval from a National Research Ethics Service Committee (NRES) for data collection and subsequent observational research using anonymised data; individual studies using CPRD data do not require further separate ethical approval. The protocol for this project was approved by the CPRD Independent Study Advisory Committee (reference:16\_189R).

## **Results**

### ***Baseline characteristics***

We identified 253,277 eligible children: 251,611 children in the term group and 1,666 children in the preterm group (Table 1). More children in the preterm group (44.9%) were from more deprived socioeconomic backgrounds (IMD 2010 fourth and fifth quintiles) compared to those in the term group (39.3%).

### ***Respiratory tract infections (RTI)***

The overall crude IR for consultations for RTI in the term and preterm groups were 7.17 (95% CI 7.15-7.19) and 9.69 (95% CI 9.42-9.96) respectively. The aIRR for the preterm group was 1.37 (95% CI 1.33-1.42,  $p < 0.001$ ) after adjustment for confounding factors (Table 2, Figure 2). Both term and preterm groups had the highest IR of consultations for RTI within their first year of life, which gradually decreased over the first five years of childhood. However, the IR in the preterm group was significantly higher than the term group in all age groups ( $p < 0.001$ ). The highest IR of consultations for RTIs were found in the most socioeconomic deprived group (Supplementary table 3). aIRRs were also increased for children in the preterm group compared to the term group (Supplementary table 3).

### ***Lower respiratory tract infections (LRTI)***

Children in the preterm group had a significantly higher overall IR for consultations for LRTI at 2.74 (95% CI 2.60-2.89) compared to 1.14 in the term group (95% CI 1.13-1.15). After adjustments, the IRR for consultations for LRTI in the preterm group in the first five years of life was 2.79 (95% CI 2.59-3.01,  $p<0.001$ ) (Table 2). The rates of consultations for LRTI in the preterm group were consistently higher than those in the term group across all age groups, peaking in the second year of life before declining. Consultations for LRTIs were the highest in the most deprived populations for both term and preterm infants. As seen with consultations for RTI, all aIRRs were increased in the preterm group (Supplementary table 4).

### ***Wheeze***

The overall IR of consultations for wheeze was more than double in the preterm cohort compared to the term cohort (Table 2), with an aIRR of 3.05 (95% CI 2.64-3.52,  $p<0.001$ ). Wheeze was more likely to be diagnosed in the first year of life for term infants but peaked in the second year of life for preterm infants. Rates of consultations for wheeze were significantly higher in the preterm population throughout all age groups and deprivation quintiles (Supplementary table 5).

### ***Antibiotic Prescriptions (Abx Px)***

Ex-preterm infants had significantly higher rates of Abx Px compared to their term counterparts with overall IR of 12.67 (95% CI 12.38-12.97) and 8.40 (95% CI 8.38-8.42) respectively (Table 2, Figure 3). The aIRR for the preterm group was 1.49 (95% CI 1.44-1.55,  $p<0.001$ ). Children in both cohorts had the highest rate of Abx Px in their second year of life before gradually decreasing. There were no significant differences in prescribing based on socioeconomic background (Supplementary table 6). The major classes of antibiotics prescribed by group are shown in Supplementary table 7.

### ***Subgroup analyses***

The PT-O<sub>2</sub> group were more likely to have lower gestational ages compared to those in the PT-Air group (Table 3). There was a significant increase in morbidity across all three respiratory outcomes and Abx Px in the PT-O<sub>2</sub> group compared to those in the PT-Air group (Table 4, Supplementary tables 8 and 9). Compared with the PT-Air group, the PT-O<sub>2</sub> had higher aIRRs for consultations for RTI (1.21, 95% CI 1.12-1.30,  $p<0.001$ ), LRTI (1.74, 95% CI 1.50-2.03,  $p<0.001$ ) and Abx Px (1.39, 95% CI 1.28-1.50,  $p<0.001$ ). PT-O<sub>2</sub> also had higher incidence rates for consultations for wheeze, however this was not statistically significant following adjustment. Rates of consultations for RTI and

LRTI observed in the PT-O<sub>2</sub> group were consistently higher than those in the PT-Air group across all age groups (Figure 3). In particular, the rate of consultations for LRTI seen in the PT-O<sub>2</sub> group was three to four times higher than that seen in the term group across all five years of early childhood.

### ***Epoch analyses***

The study cohort was divided into two 8-year epochs: Epoch 1 (1997-2005) included 87,556 children and Epoch 2 (2006-2014) included 165,721 children (Supplementary Table 10). Overall, there were no substantial differences in the aIRRs for consultations for RTI, LRTI, and wheeze between two epochs; the 95% confidence intervals for the two epochs for these outcomes overlap (Table 5). The aIRR for Abx Px decreased from 1.58 (95% CI 1.50-1.67) to 1.41 (95% CI 1.34-1.48).

### **Discussion**

This study, based on a large nationally representative sample of young children in England, highlights a vulnerable cohort of ex-preterm children with significant respiratory morbidity in early childhood compared to children born at term. Ex-preterm infants had higher rates of primary care diagnosed respiratory infections especially LRTI which are more likely to result in the need for antibiotics [30]. For ex-preterm infants discharged on home oxygen, the rates of consultations for LRTI and Abx Px are even greater and remain high throughout childhood and never fall below that of term babies across all years.

Prematurity and low birth weight were associated with a persistent increase in respiratory morbidity in early childhood. This appeared magnified for the infants in the PT-O<sub>2</sub> cohort who had significantly worse respiratory outcomes compared to those in the PT-Air cohort. The rates of consultations for RTI seen in our study are higher than those previously reported [31], however those were reported from hospital admissions for respiratory conditions. The highest rates of infection-related consultations were mostly observed in the first year of life when innate immune responses predominate, in keeping with other large hospital-based epidemiological studies previously published [32]. These infective episodes were more common in both the more deprived term and preterm groups confirming the adverse impact of social deprivation on child respiratory health.

Our study highlights the significant respiratory burden presenting to primary care in ex-preterm infants, especially those discharged on home oxygen who are more likely to have severe BPD. There is a paucity of data in this population and the rates of presentation to primary care. A number of small studies have focused on the respiratory function of these ex-preterm infants rather than the clinical



burden in the community. The long-term respiratory function of ex-preterm infants has previously been reported whereby childhood impairment of lung function is a significant predictor of abnormal longitudinal patterns of lung-function growth and decline into adulthood [33]. Gough *et al* and Yang *et al* have reported persistent adult respiratory morbidity in ex-preterm infants with BPD including more significant impairment of lung function and increased respiratory symptoms [12, 34].

As extreme preterm survival and BPD continue to rise, along with the associated lifelong respiratory morbidity, it is extremely important to explore key periods in early life amenable to interventions to improve long-term respiratory health. It is unclear who is best placed to manage and support the respiratory health of these children following discharge from the neonatal unit. The high rates of consultations for LRTI and Abx Px in the PT-O2 group would suggest these children may benefit from expert paediatric respiratory follow-up. In our study we are unable to ascertain which children had such follow-up but a previous study suggests less than 20% of extremely preterm children with moderate/severe BPD have paediatric follow-up at six years of age [35]. In the UK, British Thoracic Society (BTS) guidelines for home oxygen recommend that infants should have hospital follow-up either at a tertiary centre, or district general hospital if the general paediatrician has experience of home oxygen [14]. As respiratory physicians have the specialty expertise in managing and optimising lung health, it is currently unclear if targeted paediatric respiratory follow-up would reduce respiratory morbidity in this cohort of children; an approach the Prematurity and Respiratory Outcomes Program (PROP) in the US has identified with the need for integrated, multidisciplinary research and clinical teams [36].

Our study aimed to report on primary care consultations where general practitioners (GPs) make the clinical diagnosis of infection and decide if antibiotics are indicated. Higher levels of anxiety amongst parents with ex-preterm infants may lead to increased health-seeking behaviour [37]. Equally, GPs may also be more anxious about this cohort of children given their clinical history or co-morbidities and so have lower thresholds to prescribe antibiotics for such infections. These could contribute to the high rates of Abx Px seen prescribed to both preterm cohorts in our study. Antimicrobial resistance is a serious global concern at a time when prescribing antibiotics is at an all-time high [38], therefore additional parental education and support for GPs could help improve antimicrobial stewardship in these children.

Our study is the largest to date, from a robust and well validated data source [22], quantifying a previously unrecorded burden of primary healthcare utilisation and respiratory morbidity in a recent ex-preterm population. Previous studies in this population have focused on hospital admissions only or did not allow comparison between preterm infants discharged with or without home oxygen and term infants in the same population [15, 31].

There appears to be no significant differences over the study time period as observed by the epoch analysis with consultations for infection and wheeze rate differences between term and preterm unchanged. Abx Px rates remain higher for the preterm population although the difference appears slightly lower in recent years. The reasons for this are unclear, especially with similar rates of infection being diagnosed, but are perhaps related to better antibiotic stewardship, smaller numbers in the preterm groups as a consequence of epoch division, or other mechanisms not measured in this study.

There are a number of limitations of this study including the retrospective nature, although data were collected prospectively. The lack of paired respiratory diagnosis and Abx Px makes it difficult to directly link these episodes although we only included antibiotics which may be used for respiratory infections. Some of these drugs could be used for other infections, for example, trimethoprim is used for urinary tract infections. The database analysis does not allow us to classify which preterm children had a diagnosis of BPD. We therefore used home oxygen as a proxy for more severe respiratory disease although this requirement can be related to morbidities, other than BPD, or other factors we haven't modelled such as GA. Prospective data on which specialists undertake outpatient follow-up of the preterm group would also help understand any impact on respiratory morbidity. The present study focused on primary care consultations which have not been studied in such detail. Extension of this study to include hospital attendances was beyond the scope of this study but could be useful supporting the morbidity observed as previously reported [31, 39].

Finally, we also had no data on children's exposure to cigarette smoke, either in-utero or passive exposure during childhood. Recording of smoking status of pregnant women in primary care data is incomplete [40] and data recorded may not accurately reflect women's true smoking status. Nevertheless, we acknowledge the impact of maternal smoking on health and lung function, including the increasing prevalence of childhood respiratory infections and wheeze [36]. As smoking is more prevalent in lower socioeconomic populations this could contribute to some of the additional morbidity observed in the preterm groups

## **Conclusions**

Our findings highlight significant respiratory morbidity in ex-preterm infants, especially those discharged home on oxygen and likely to have more severe BPD, in the first five years of life. With increasing survival and BPD in this population there could be an increased health resources implication for both hospital physicians and GPs. Additional research is needed on prevention strategies to minimise respiratory morbidity and improve long-term lung function for these high-risk

children. Key to this is the identification of core respiratory outcomes most important for both clinicians and parents, and for targeted interventions to ameliorate these. Longer term respiratory follow up is essential as more of these vulnerable infants survive to reduce the burden for children, their families and healthcare services. Who is best placed to undertake long-term respiratory follow-up remains to be established.

**Table 1:** Baseline characteristics of children in study

Characteristics	Term: $\geq 37/40$ and $\geq 2500$ g N = 251,611	Preterm: $< 32/40$ and $< 1500$ g N = 1,666	p-value
Male sex, n (%)	130,220 (51.8)	815 (48.9)	0.021
Gestational age at birth (weeks), median (IQR)	40 (39-41)	28 (27-30)	<0.001
Birth weight in g, median (IQR)	3459 (3180-3745)	1168 (966-1330)	<0.001
IMD 2010 quintile, n (%)			
1 (least deprived)	54,154 (21.5)	280 (16.8)	<0.001
2	51,410 (20.4)	330 (19.8)	
3	46,687 (18.6)	305 (18.3)	
4	49,899 (19.8)	364 (21.9)	
5 (most deprived)	49,071 (19.5)	383 (23.0)	
Missing	390 (0.2)	4 (0.2)	
Age at the beginning of follow up in days, median (IQR)	25 (14-43)	49 (29-75)	<0.001
Length of follow-up in months, median (IQR)	48 (24-60)	49 (23-60)	<0.001
Congenital anomalies, n (%)	6,158 (2.5)	333 (20)	<0.001

**Table 2:** Overall incidence rates and incidence rate ratios (unadjusted and adjusted) for respiratory outcomes in the first five years of life in term and preterm cohorts

	Term		Preterm		Unadjusted IRR (95% CI)	Adjusted IRR <sup>#</sup> (95% CI)
	Events	Rate (95% CI)	Events	Rate (95% CI)		
<b>RTI</b>	451,438	7.17 (7.15-7.19)	4,940	9.69 (9.42-9.96)	1.35** (1.31-1.39)	1.37** (1.33-1.42)
<b>LRTI</b>	71,929	1.14 (1.13-1.15)	1,397	2.74 (2.60-2.89)	2.40** (2.27-2.53)	2.79** (2.59-3.01)
<b>Wheeze</b>	32,529	0.52 (0.51-0.52)	608	1.19 (1.10-1.29)	2.31** (2.13-2.50)	3.05** (2.64-3.52)
<b>Abx Px</b>	711,743	8.40 (8.38-8.42)	6,971	12.67 (12.38-12.97)	1.51** (1.47-1.54)	1.49** (1.44-1.55)

All rates are described as per 10 person years; CI= confidence interval; IRR= incidence rate ratio;

<sup>#</sup> Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; \*\*p-value < 0.001

**Table 3:** Baseline characteristics of preterm children with (PT-O<sub>2</sub>) and without (PT-Air) home oxygen

<b>Characteristics</b>	<b>PT-Air (N = 1,217)</b>	<b>PT-O<sub>2</sub> (N = 449)</b>
Male sex, n (%)	575 (47.2)	240 (53.5)
Gestational age at birth (weeks), median (IQR)	29 (28-30)	26 (25-28)
Birth weight in g, median (IQR)	1245 (1077-1360)	955 (794-1095)
IMD 2010 quintile, n (%)		
1 (least deprived)	207 (17.0)	73 (16.3)
2	235 (19.3)	95 (21.2)
3	231 (19.0)	74 (16.5)
4	259 (21.3)	105 (23.4)
5 (most deprived)	284 (23.3)	99 (22.0)
Missing	1 (0.1)	3 (0.6)
Congenital anomalies, n (%)	175 (14.4)	158 (35.2)

**Table 4:** Overall incidence rates and incidence rate ratios (unadjusted and adjusted) for respiratory outcomes in the first five years of life PT-Air and PT-O<sub>2</sub> cohorts

	<b>PT-Air</b>		<b>PT-O<sub>2</sub></b>		<b>Unadjusted IRR (95% CI)</b>	<b>Adjusted IRR<sup>#</sup> (95% CI)</b>
	<b>Events</b>	<b>Rate (95% CI)</b>	<b>Events</b>	<b>Rate (95% CI)</b>		
<b>RTI</b>	3,431	9.16 (8.85-9.47)	1,509	11.16 (10.62-11.74)	1.22** (1.15-1.30)	1.21** (1.12-1.30)
<b>LRTI</b>	875	2.33 (2.19-2.49)	522	3.86 (3.54-4.21)	1.65** (1.48-1.85)	1.74** (1.50-2.03)
<b>Wheeze</b>	426	1.14 (1.03-1.25)	182	1.35 (1.16-1.56)	1.18* (0.99-1.41)	1.10 (0.86-1.42)
<b>Abx Px</b>	4,768	11.63 (11.31-11.97)	2,203	15.71 (15.06-16.38)	1.35** (1.28-1.42)	1.39** (1.28-1.50)

All rates are described as per 10 person years; CI= confidence interval; IRR= incidence rate ratio;


# Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; \*\*p-value < 0.001; \*p-value < 0.05

**Table 5:** Epoch analyses showing unadjusted and adjusted IRRs between term and preterm cohorts


	Epoch 1 (1997-2005)		Epoch 2 (2006-2014)	
	Unadjusted IRR (95% CI)	Adjusted IRR <sup>#</sup> (95% CI)	Unadjusted IRR (95% CI)	Adjusted IRR <sup>#</sup> (95% CI)
<b>RTI</b>	1.34** (1.28-1.40)	1.36** (1.29-1.43)	1.36** (1.31-1.42)	1.37** (1.30-1.43)
<b>LRTI</b>	2.24** (2.07-2.43)	2.64** (2.36-2.96)	2.50** (2.33-2.69)	2.81** (2.55-3.11)
<b>Wheeze</b>	1.95** (1.71-2.22)	2.48** (1.98-3.10)	2.60** (2.34-2.88)	3.36** (2.79-4.05)
<b>Abx Px</b>	1.52** (1.47-1.58)	1.58** (1.50-1.67)	1.49** (1.44-1.54)	1.41** (1.34-1.48)

<sup>#</sup> Adjusted for age, sex, IMD 2010 quintile, congenital abnormalities; \*\*p-value < 0.001

**Figure 1:** Flow diagram illustrating the number of children included and excluded from the cohort at each stage of data cleaning. GA: gestational age; BW: birthweight




**Figure 2:** Overall adjusted IRRs for respiratory outcomes comparing term and preterm cohorts over five years of follow-up





**Figure 3:** Crude incidence rates of respiratory outcomes (RTI, LRTI, wheeze) and Abx Px across all three cohorts over the first five years of childhood



## References

1. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. *The Lancet* 2006; 367: 1421–1431.
2. Siffel C, Kistler KD, Lewis JFM, Sarda SP. Global incidence of bronchopulmonary dysplasia among extremely preterm infants: a systematic literature review. *J. Matern. Fetal Neonatal Med.* 2019; : 1–11.
3. Duijts L, van Meel ER, Moschino L, Baraldi E, Barnhoorn M, Bramer WM, *et al.* European Respiratory Society guideline on long term management of children with bronchopulmonary dysplasia. *Eur. Respir. J.* 2019; : 1900788.
4. Owen LS, Cheong JLY, Davis PG. Bronchopulmonary dysplasia as a trial endpoint: time for re-evaluation? *Lancet Child Adolesc. Health* 2019; .
5. Eber E, Zach MS. Long term sequelae of bronchopulmonary dysplasia (chronic lung disease of infancy). *Thorax* 2001; 56: 317–323.
6. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, *et al.* Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. *Pediatrics* 2005; 116: 1353–1360.
7. Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, *et al.* Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. *JAMA* 2015; 314: 1039.
8. Lui K, Lee SK, Kusuda S, Adams M, Vento M, Reichman B, *et al.* Trends in Outcomes for Neonates Born Very Preterm and Very Low Birth Weight in 11 High-Income Countries. *J. Pediatr.* 2019; 215: 32-40.e14.
9. Chawanpaiboon S, Vogel JP, Moller A-B, Lumbiganon P, Petzold M, Hogan D, *et al.* Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. *Lancet Glob. Health* 2019; 7: e37–e46.
10. Islam JY, Keller RL, Aschner JL, Hartert TV, Moore PE. Understanding the Short- and Long-Term Respiratory Outcomes of Prematurity and Bronchopulmonary Dysplasia. *Am. J. Respir. Crit. Care Med.* 2015; 192: 134–156.
11. Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia: Epidemiology of Bronchopulmonary Dysplasia. *Birt. Defects Res. A. Clin. Mol. Teratol.* 2014; 100: 145–157.
12. Gough A, Linden M, Spence D, Patterson CC, Halliday HL, McGarvey LPA. Impaired lung function and health status in adult survivors of bronchopulmonary dysplasia. *Eur. Respir. J.* 2014; 43: 808–816.
13. Álvarez-Fuente M, Arruza L, Muro M, Zozaya C, Avila A, López-Ortego P, *et al.* The economic impact of prematurity and bronchopulmonary dysplasia. *Eur. J. Pediatr.* 2017; 176: 1587–1593.
14. Balfour-Lynn IM, Field DJ, Gringras P, Hicks B, Jardine E, Jones RC, *et al.* BTS guidelines for home oxygen in children. *Thorax* 2009; 64 Suppl 2: ii1-26.

15. Greenough A, Alexander J, Burgess S, Chetcuti P a. J, Cox S, Lenney W, *et al.* Home oxygen status and rehospitalisation and primary care requirements of infants with chronic lung disease. *Arch. Dis. Child.* 2002; 86: 40–43.
16. Vrijlandt EJLE, Kerstjens JM, Duiverman EJ, Bos AF, Reijneveld SA. Moderately Preterm Children Have More Respiratory Problems during Their First 5 Years of Life Than Children Born Full Term. *Am. J. Respir. Crit. Care Med.* 2013; 187: 1234–1240.
17. Montgomery S, Bahmanyar S, Brus O, Hussein O, Kosma P, Palme-Kilander C. Respiratory infections in preterm infants and subsequent asthma: a cohort study. *BMJ Open* 2013; 3: e004034.
18. Data | CPRD [Internet]. [cited 2019 Nov 14].Available from: <https://cprd.com/Data>.
19. Hospital Episode Statistics (HES) [Internet]. NHS Digit. [cited 2018 May 18].Available from: <https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics>.
20. CPRD linked data | CPRD [Internet]. [cited 2019 Nov 14].Available from: <https://www.cprd.com/linked-data>.
21. Padmanabhan S, Carty L, Cameron E, Ghosh RE, Williams R, Strongman H. Approach to record linkage of primary care data from Clinical Practice Research Datalink to other health-related patient data: overview and implications. *Eur. J. Epidemiol.* 2019; 34: 91–99.
22. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data Resource Profile: Clinical Practice Research Datalink (CPRD). *Int. J. Epidemiol.* 2015; 44: 827–836.
23. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA. Cross sectional stature and weight reference curves for the UK, 1990. *Arch. Dis. Child.* 1995; 73: 17–24.
24. Ban L, Gibson JE, West J, Tata LJ. Association between perinatal depression in mothers and the risk of childhood infections in offspring: a population-based cohort study. *BMC Public Health* 2010; 10: 799.
25. Bannister J, Szatkowski L, Sharkey D, Tan S, Fiaschi L, Ban L. Early Life Incidence of Gastrointestinal and Respiratory Infections in Children With Gastroschisis: A Cohort Study. *J. Pediatr. Gastroenterol. Nutr.* 2018; 67: 580–585.
26. BNF for Children: British National Formulary - NICE [Internet]. [cited 2020 Jan 7].Available from: <https://bnfc.nice.org.uk/>.
27. English indices of deprivation 2010 [Internet]. GOV.UK [cited 2019 Nov 20].Available from: <https://www.gov.uk/government/statistics/english-indices-of-deprivation-2010>.
28. Headline results from the Indices of Deprivation 2010 | OCSI [Internet]. [cited 2019 Nov 20].Available from: <https://ocsi.uk/2011/03/24/headline-results-from-the-indices-of-deprivation-2010/>.
29. European Platform on Rare Disease Registration [Internet]. [cited 2019 Oct 31].Available from: <https://eu-rd-platform.jrc.ec.europa.eu>.
30. Overview | Respiratory tract infections (self-limiting): prescribing antibiotics | Guidance | NICE [Internet]. [cited 2020 Jan 23].Available from: <https://www.nice.org.uk/guidance/cg69>.

31. Paranjothy S, Dunstan F, Watkins WJ, Hyatt M, Demmler JC, Lyons RA, Fone D. Gestational age, birth weight, and risk of respiratory hospital admission in childhood. *Pediatrics* 2013; 132: e1562-1569.
32. Miller JE, Hammond GC, Strunk T, Moore HC, Leonard H, Carter KW, *et al.* Association of gestational age and growth measures at birth with infection-related admissions to hospital throughout childhood: a population-based, data-linkage study from Western Australia. *Lancet Infect. Dis.* 2016; 16: 952–961.
33. McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, *et al.* Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. *N. Engl. J. Med.* 2016; 374: 1842–1852.
34. Yang J, Kingsford RA, Horwood J, Epton MJ, Swanney MP, Stanton J, Darlow BA. Lung Function of Adults Born at Very Low Birth Weight. *Pediatrics* [Internet] 2020 [cited 2020 Jan 29]; Available from: <https://pediatrics.aappublications.org/content/early/2020/01/02/peds.2019-2359>.
35. Hennessy EM, Bracewell MA, Wood N, Wolke D, Costeloe K, Gibson A, *et al.* Respiratory health in pre-school and school age children following extremely preterm birth. *Arch. Dis. Child.* 2008; 93: 1037–1043.
36. Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV, *et al.* Bronchopulmonary Dysplasia: Executive Summary of a Workshop. *J. Pediatr.* 2018; 197: 300–308.
37. Holditch-Davis D, Santos H, Levy J, White-Traut R, O’Shea TM, Geraldo V, David R. Patterns of Psychological Distress in Mothers of Preterm Infants. *Infant Behav. Dev.* 2015; 41: 154–163.
38. Palin V, Mölter A, Belmonte M, Ashcroft DM, White A, Welfare W, van Staa T. Antibiotic prescribing for common infections in UK general practice: variability and drivers. *J. Antimicrob. Chemother.* 2019; 74: 2440–2450.
39. Haataja P, Korhonen P, Ojala R, Hirvonen M, Korppi M, Gissler M, *et al.* Hospital admissions for lower respiratory tract infections in children born moderately/late preterm. *Pediatr. Pulmonol.* 2018; 53: 209–217.
40. Dhalwani NN, Tata LJ, Coleman T, Fleming KM, Szatkowski L. Completeness of Maternal Smoking Status Recording during Pregnancy in United Kingdom Primary Care Data. Sun Q, editor. *PLoS ONE* 2013; 8: e72218.

**Online supplementary material**

**Supplementary Table 1:** Distribution of our study population according to gestational age in comparison to Office for National Statistics (ONS) data 2010. ONS data includes all live births, CPRD data only includes patients surviving discharge from hospital and registering with primary care.

<b>Gestational age (weeks)</b>	<b>ONS 2010, n (%)</b>	<b>Redefined CPRD population, n (%)</b>
<24	750 (0.11)	112 (0.04)
24-27	2,329 (0.33)	3706 (1.28)
28-31	5,757 (0.81)	5,552 (1.92)
32-36	41,914 (5.89)	19,342 (6.70)
37-42	630,797 (88.64)	259,148 (89.79)
Post-term, >42	30,065 (4.22)	753 (0.26)
Total	711,612	288,613

**Supplementary Table 2:** Distribution of our study population according to birthweight in comparison to Office for National Statistics (ONS) data 2010. ONS data includes all live births, CPRD data only includes patients surviving discharge from hospital and registering with primary care.

<b>Birthweight (grams)</b>	<b>ONS 2010, n (%)</b>	<b>Redefined CPRD population, n (%)</b>
<1000	4,170 (0.58)	586 (0.20)
1000-1499	4,591 (0.64)	1,883 (0.65)
1500-2499	41,484 (5.82)	18,977 (6.58)
2500-3999	581,253 (81.50)	239,041 (82.82)
>4000	81,759 (11.46)	28,126 (9.75)
Total	713,257	288,613

**Supplementary Table 3:** Incidence rates and incidence rate ratios of respiratory tract infections (RTI) between groups of children

	Term: $\geq 37/40$ and $\geq 2500$ g		Preterm: $< 32/40$ and $< 1500$ g					
	Events	Rate per 10 person years (95% CI)	Events	Rate per 10 person years (95% CI)	Unadjusted IRR (95% CI)	P value	Adjusted IRR <sup>#</sup> (95% CI)	P value
<b>Overall</b>	451,438	7.17 (7.15-7.19)	4,940	9.69 (9.42-9.96)	1.35 (1.31-1.39)	<0.001	1.37 (1.33-1.42)	<0.001
<b>Age (years)</b>								
0-1	172,887	10.17 (10.13-10.22)	1,601	12.65 (12.05-13.29)	1.24 (1.18-1.31)	<0.001	1.21 (1.15-1.28)	<0.001
1-2	126,278	8.09 (8.04-8.13)	1,463	11.66 (11.07-12.27)	1.44 (1.37-1.52)	<0.001	1.50 (1.40-1.61)	<0.001
2-3	70,146	5.60 (5.56-5.65)	886	8.70 (8.14-9.29)	1.55 (1.45-1.66)	<0.001	1.59 (1.45-1.75)	<0.001
3-4	49,911	4.99 (4.96-5.04)	595	7.01 (6.47-7.6)	1.40 (1.29-1.53)	<0.001	1.41 (1.26-1.57)	<0.001
4-5	32,216	4.09 (4.05-4.14)	395	5.56 (5.03-6.13)	1.36 (1.23-1.50)	<0.001	1.36 (1.19-1.57)	<0.001
<b>Sex</b>								
Male	245,307	7.53 (7.50-7.56)	2,464	10.0 (9.61-10.4)	1.33 (1.28-1.38)	<0.001	1.33 (1.27-1.40)	<0.001
Female	206,131	6.78 (6.75-6.81)	2,476	9.40 (9.03-9.77)	1.39 (1.33-1.44)	<0.001	1.42 (1.35-1.49)	<0.001
<b>IMD 2010 quintile</b>								
1 (least deprived)	98,082	7.14 (7.10-7.18)	803	8.77 (8.19-9.40)	1.23 (1.14-1.32)	<0.001	1.25 (1.15-1.36)	<0.001
2	90,665	6.99 (6.95-7.04)	1,020	9.44 (8.88-10.04)	1.35 (1.27-1.44)	<0.001	1.37 (1.27-1.48)	<0.001
3	81,032	7.01 (6.96-7.06)	879	9.58 (8.96-10.23)	1.37 (1.28-1.46)	<0.001	1.43 (1.32-1.55)	<0.001
4	89,677	7.19 (7.15-7.24)	1,068	10.09 (9.50-10.72)	1.40 (1.32-1.49)	<0.001	1.41 (1.30-1.52)	<0.001
5 (most deprived)	91,274	7.51 (7.46-7.56)	1,157	10.39 (9.80-11.00)	1.38 (1.30-1.47)	<0.001	1.40 (1.30-1.51)	<0.001
Missing	708	7.84 (7.28-8.44)	13	9.99 (5.80-17.20)	1.27 (0.67-2.19)	0.19	1.07 (0.55-2.09)	0.84
<b>Congenital anomalies (CA)</b>								
No CA	437,238	7.13 (7.11-7.15)	3,805	9.39 (9.09-9.69)	1.32 (1.28-1.36)	<0.001	1.40 (1.35-1.45)	<0.001
Has CA	14,200	8.69 (8.55-8.84)	1,135	10.86 (10.24-11.51)	1.25 (1.17-1.33)	<0.001	1.28 (1.19-1.38)	<0.001

<sup>#</sup> Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; CI= confidence interval; IRR= incidence rate ratio

**Supplementary Table 4:** Incidence rates and incidence rate ratios of lower respiratory tract infections (LRTI) between groups of children

	Term: $\geq 37/40$ and $\geq 2500$ g		Preterm: $< 32/40$ and $< 1500$ g					
	Events	Rate per 10 person years (95% CI)	Events	Rate per 10 person years (95% CI)	Unadjusted IRR (95% CI)	P value	Adjusted IRR <sup>#</sup> (95% CI)	P value
<b>Overall</b>	71,929	1.14 (1.13-1.15)	1,397	2.74 (2.60-2.89)	2.40 (2.27-2.53)	<0.001	2.79 (2.59-3.01)	<0.001
<b>Age (years)</b>								
0-1	29,630	1.74 (1.72-1.76)	520	2.36 (2.16-2.57)	2.36 (2.16-2.57)	<0.001	2.36 (2.13-2.61)	<0.001
1-2	20,645	1.32 (1.30-1.34)	422	3.36 (3.06-3.70)	2.54 (2.30-2.80)	<0.001	3.61 (3.02-4.32)	<0.001
2-3	10,753	0.86 (0.84-0.88)	227	2.23 (1.96-2.54)	2.59 (2.26-2.96)	<0.001	3.39 (2.71-4.24)	<0.001
3-4	6,794	0.68 (0.66-0.70)	145	1.71 (1.45-2.01)	2.51 (2.11-2.96)	<0.001	3.36 (2.55-4.43)	<0.001
4-5	4,107	0.52 (0.51-0.54)	83	1.17 (0.94-1.45)	2.24 (1.78-2.78)	<0.001	2.52 (1.79-3.54)	<0.001
<b>Sex</b>								
Male	41,097	1.26 (1.25-1.27)	701	2.84 (2.64-3.06)	2.26 (2.09-2.43)	<0.001	2.59 (2.33-2.88)	<0.001
Female	30,832	1.01 (1.00-1.03)	696	2.64 (2.45-2.85)	2.60 (2.41-2.81)	<0.001	3.01 (2.71-3.35)	<0.001
<b>IMD 2010 quintile</b>								
1 (least deprived)	15,486	1.13 (1.11-1.15)	232	2.53 (2.23-2.88)	2.25 (1.97-2.56)	<0.001	2.58 (2.16-3.08)	<0.001
2	14,261	1.10 (1.08-1.12)	286	2.65 (2.36-2.97)	2.41 (2.13-2.71)	<0.001	2.82 (2.39-3.33)	<0.001
3	12,748	1.10 (1.08-1.12)	235	2.56 (2.25-2.91)	2.32 (2.03-2.64)	<0.001	2.77 (2.31-3.33)	<0.001
4	14,344	1.15 (1.13-1.17)	290	2.74 (2.44-3.07)	2.38 (2.11-2.68)	<0.001	2.70 (2.28-3.19)	<0.001
5 (most deprived)	14,989	1.23 (1.21-1.25)	349	3.13 (2.82-3.48)	2.54 (2.28-2.83)	<0.001	3.03 (2.60-3.53)	<0.001
Missing	101	1.12 (0.92-1.36)	5	3.84 (1.60-9.28)	3.43 (1.09-8.28)	0.01	3.61 (0.78-16.77)	0.10
<b>Congenital anomalies (CA)</b>								
No CA	69,240	1.13 (1.12-1.14)	1,029	2.54 (2.39-2.70)	2.25 (2.11-2.39)	<0.001	2.84 (2.61-3.09)	<0.001
Has CA	2,689	1.64 (1.59-1.71)	368	3.52 (3.18-3.90)	2.14 (1.91-2.39)	<0.001	2.60 (2.22-3.03)	<0.001

<sup>#</sup> Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; CI= confidence interval; IRR= incidence rate ratio



**Supplementary Table 5:** Incidence rates and incidence rate ratios of wheeze between groups of children

	Term: $\geq 37/40$ and $\geq 2500$ g		Preterm: $< 32/40$ and $< 1500$ g					
	Events	Rate per 10 person years (95% CI)	Events	Rate per 10 person years (95% CI)	Unadjusted IRR (95% CI)	P value	Adjusted IRR <sup>#</sup> (95% CI)	P value
<b>Overall</b>	32,529	0.52 (0.51-0.52)	608	1.19 (1.10-1.29)	2.31 (2.13-2.50)	<0.001	3.05 (2.64-3.52)	<0.001
<b>Age (years)</b>								
0-1	13,336	0.78 (0.77-0.80)	218	1.72 (1.51-1.97)	2.20 (1.91-2.51)	<0.001	2.33 (1.93-2.81)	<0.001
1-2	9,695	0.62 (0.61-0.63)	234	1.86 (1.64-2.12)	3.00 (2.63-3.42)	<0.001	5.97 (4.27-8.36)	<0.001
2-3	4,858	0.39 (0.38-0.40)	92	0.90 (0.74-1.11)	2.33 (1.87-2.86)	<0.001	3.88 (2.41-6.25)	<0.001
3-4	3,016	0.30 (0.29-0.31)	40	0.47 (0.35-0.64)	1.56 (1.11-2.13)	0.004	1.60 (0.96-2.68)	0.07
4-5	1,624	0.21 (0.20-0.22)	24	0.34 (0.23-0.50)	1.64 (1.05-2.44)	0.01	2.00 (0.98-4.07)	0.06
<b>Sex</b>								
Male	20,813	0.64 (0.63-0.65)	371	1.51 (1.36-1.67)	2.36 (2.12-2.61)	<0.001	3.04 (2.51-3.67)	<0.001
Female	11,716	0.39 (0.38-0.39)	237	0.90 (0.79-1.02)	2.33 (2.04-2.65)	<0.001	3.18 (2.51-4.02)	<0.001
<b>IMD 2010 quintile</b>								
1 (least deprived)	7,358	0.54 (0.52-0.55)	102	1.11 (0.92-1.35)	2.08 (1.69-2.53)	<0.001	2.49 (1.76-3.52)	<0.001
2	6,522	0.50 (0.49-0.52)	135	1.25 (1.06-1.48)	2.48 (2.08-2.95)	<0.001	3.37 (2.46-4.63)	<0.001
3	5,835	0.50 (0.49-0.52)	108	1.18 (0.97-1.42)	2.33 (1.91-2.82)	<0.001	3.23 (2.29-4.56)	<0.001
4	6,101	0.49 (0.48-0.50)	106	1.00 (0.83-1.21)	2.05 (1.67-2.48)	<0.001	2.52 (1.82-3.48)	<0.001
5 (most deprived)	6,648	0.55 (0.53-0.56)	156	1.40 (1.20-1.64)	2.56 (2.17-3.00)	<0.001	3.77 (2.83-5.04)	<0.001
Missing	65	0.72 (0.56-0.92)	1	0.77 (0.11-5.45)	1.07 (0.03-6.16)	0.43	1.09 (0.05-24.11)	0.96
<b>Congenital anomalies (CA)</b>								
No CA	31,456	0.51 (0.51-0.52)	443	1.09 (1.00-1.20)	2.13 (1.94-2.34)	<0.001	2.99 (2.53-3.52)	<0.001
Has CA	1,073	0.66 (0.62-0.70)	165	1.58 (1.36-1.84)	2.40 (2.03-2.83)	<0.001	3.37 (2.56-4.45)	<0.001

<sup>#</sup> Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; CI= confidence interval; IRR= incidence rate ratio

**Supplementary Table 6:** Incidence rates and incidence rate ratios of antibiotic prescriptions between groups of children

	Term: $\geq 37/40$ and $\geq 2500$ g		Preterm: $< 32/40$ and $< 1500$ g					
	Events	Rate per 10 person years (95% CI)	Events	Rate per 10 person years (95% CI)	Unadjusted IRR (95% CI)	P value	Adjusted IRR <sup>#</sup> (95% CI)	P value
<b>Overall</b>	711,743	8.40 (8.38-8.42)	6,971	12.67 (12.38-12.97)	1.51 (1.47-1.54)	<0.001	1.49 (1.44-1.55)	<0.001
<b>Age (years)</b>								
0-1	180,426	8.15 (8.11-8.19)	1,401	10.30 (9.77-10.85)	1.26 (1.20-1.33)	<0.001	1.14 (1.07-1.22)	<0.001
1-2	212,120	10.29 (10.25-10.34)	2,155	15.96 (15.30-16.65)	1.55 (1.49-1.62)	<0.001	1.55 (1.45-1.66)	<0.001
2-3	135,874	8.06 (8.01-8.10)	1,475	13.36 (12.69-14.05)	1.66 (1.57-1.74)	<0.001	1.75 (1.60-1.90)	<0.001
3-4	108,033	7.82 (7.77-7.86)	1,113	12.11 (11.42-12.85)	1.55 (1.46-1.64)	<0.001	1.53 (1.39-1.68)	<0.001
4-5	75,290	6.68 (6.63-6.72)	827	10.76 (10.05-11.52)	1.61 (1.50-1.73)	<0.001	1.66 (1.48-1.86)	<0.001
<b>Sex</b>								
Male	389,818	8.89 (8.86-8.91)	3,692	13.76 (13.32-14.21)	1.55 (1.50-1.60)	<0.001	1.54 (1.46-1.62)	<0.001
Female	321,925	7.88 (7.85-7.91)	3,279	11.63 (11.24-12.04)	1.48 (1.43-1.53)	<0.001	1.45 (1.37-1.53)	<0.001
<b>IMD 2010 quintile</b>								
1 (least deprived)	161,597	8.40 (8.36-8.44)	1,266	12.83 (12.14-13.55)	1.53 (1.44-1.61)	<0.001	1.70 (1.56-1.86)	<0.001
2	147,517	8.35 (8.31-8.39)	1,397	12.43 (11.80-13.55)	1.49 (1.41-1.57)	<0.001	1.48 (1.36-1.61)	<0.001
3	129,433	8.36 (8.31-8.41)	1,267	12.48 (11.82-13.19)	1.49 (1.41-1.58)	<0.001	1.43 (1.31-1.55)	<0.001
4	138,038	8.49 (8.45-8.54)	1,530	13.34 (12.69-14.02)	1.57 (1.49-1.65)	<0.001	1.49 (1.38-1.61)	<0.001
5 (most deprived)	134,113	8.40 (8.36-8.45)	1,500	12.33 (11.72-12.97)	1.47 (1.39-1.54)	<0.001	1.42 (1.32-1.54)	<0.001
Missing	1,045	8.81 (8.29-9.36)	11	8.45 (4.68-15.26)	-0.04 (-0.54-0.47)	0.46	0.64 (0.30-1.38)	0.26
<b>Congenital anomalies (CA)</b>								
No CA	679,215	8.24 (8.22-8.26)	5,203	11.87 (11.55-12.19)	1.44 (1.40-1.48)	<0.001	1.65 (1.58-1.72)	<0.001
Has CA	32,528	14.42 (14.26-14.58)	1,768	15.82 (15.10-16.57)	1.10 (1.05-1.15)	<0.001	1.06 (0.98-1.15)	0.13

<sup>#</sup> Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; CI= confidence interval; IRR= incidence rate ratio

**Supplementary Table 7:** Incidence rates of antibiotic prescriptions (by antibiotics class) between groups of children

	Term		PT-Air		PT-O <sub>2</sub>	
	Events	Rate per 10 person years (95% CI)	Events	Rate per 10 person years (95% CI)	Events	Rate per 10 person years (95% CI)
<b>Overall</b>	711,743	8.40 (8.38-8.42)	4,768	11.63 (11.31-11.97)	2,203	15.71 (15.06-16.38)
<b>Class of antibiotics</b>						
Broad-spectrum penicillins	704,503	8.32 (8.30-8.34)	4,496	10.97 (10.65-11.29)	1,923	13.71 (13.11-14.34)
Macrolides	138,507	1.64 (1.63-1.64)	956	2.33 (2.19-2.48)	415	2.96 (2.69-3.26)
Benzylpenicillin and phenoxymethylpenicillin	97,269	1.15 (1.14-1.16)	411	1.00 (0.91-1.10)	160	1.14 (0.98-1.33)
Penicillinase-resistant penicillins	62,918	0.74 (0.74-0.75)	272	0.66 (0.59-0.75)	77	0.55 (0.44-0.69)
Sulphonamides and trimethoprim	52,317	0.62 (0.61-0.62)	469	1.14 (1.05-1.25)	223	1.59 (1.39-1.81)
Cephalosporins	33,356	0.39 (0.39-0.40)	315	0.77 (0.69-0.86)	204	1.45 (1.27-1.67)

**Supplementary Table 8:** Incidence rate ratios of consultations for lower respiratory tract infections (LRTI) and antibiotic prescriptions (Abx Px) between children in PT-Air and PT-O<sub>2</sub>

	Lower Respiratory Tract Infections				Antibiotic Prescriptions (Abx Px)			
	Unadjusted IRR (95% CI)	P value	Adjusted IRR <sup>#</sup> (95% CI)	P value	Unadjusted IRR (95% CI)	P value	Adjusted IRR <sup>#</sup> (95% CI)	P value
<b>Overall</b>	1.65 (1.48-1.85)	<0.001	1.74 (1.50-2.03)	<0.001	1.35 (1.28-1.42)	<0.001	1.39 (1.28-1.50)	<0.001
<b>Age</b>								
0-1	1.46 (1.21-1.75)	<0.001	1.39 (1.14-1.69)	0.001	1.15 (1.02-1.29)	0.009	1.12 (0.96-1.31)	0.14
1-2	1.56 (1.27-1.91)	<0.001	1.63 (1.19-2.25)	0.003	1.35 (1.24-1.48)	<0.001	1.32 (1.15-1.52)	<0.001
2-3	2.03 (1.55-2.67)	<0.001	2.65 (1.77-3.96)	<0.001	1.43 (1.28-1.60)	<0.001	1.51 (1.26-1.82)	<0.001
3-4	1.61 (1.12-2.28)	0.004	1.81 (1.02-3.23)	0.04	1.43 (1.26-1.62)	<0.001	1.73 (1.40-2.14)	<0.001
4-5	2.31 (1.45-3.64)	<0.001	2.58 (1.38-4.83)	0.003	1.38 (1.19-1.61)	<0.001	1.38 (1.07-1.78)	0.01
<b>Sex</b>								
Male	1.87 (1.60-2.18)	<0.001	2.12 (1.73-2.61)	<0.001	1.45 (1.36-1.55)	<0.001	1.65 (1.49-1.83)	<0.001
Female	1.44 (1.22-1.69)	<0.001	1.43 (1.15-1.78)	0.001	1.21 (1.12-1.30)	<0.001	1.33 (1.18-1.49)	<0.001
<b>IMD 2010 quintile</b>								
1 (least deprived)	1.66 (1.26-2.18)	<0.001	1.82 (1.29-2.56)	0.001	1.57 (1.40-1.77)	<0.001	2.17 (1.77-2.65)	<0.001
2	1.60 (1.25-2.04)	<0.001	1.57 (1.11-2.22)	0.01	1.25 (1.12-1.40)	<0.001	1.25 (1.04-1.51)	0.02
3	1.88 (1.42-2.48)	<0.001	2.27 (1.57-3.27)	<0.001	1.34 (1.18-1.52)	<0.001	1.38 (1.15-1.66)	0.001
4	1.64 (1.28-2.09)	<0.001	1.61 (1.19-2.20)	0.002	1.20 (1.07-1.34)	<0.001	1.06 (0.90-1.26)	0.48
5 (most deprived)	1.54 (1.23-1.93)	<0.001	1.64 (1.21-2.23)	0.002	1.46 (1.31-1.63)	<0.001	1.42 (1.21-1.67)	<0.001
Missing	.	0.05	.	.	0.99 (0.25-4.63)	0.49	1.01 (0.22-4.66)	0.99
<b>Congenital anomalies</b>								
No CA	1.57 (1.37-1.79)	<0.001	1.78 (1.49-2.14)	<0.001	1.20 (1.13-1.28)	<0.001	1.31 (1.19-1.44)	<0.001
Has CA	1.61 (1.30-1.99)	<0.001	1.66 (1.28-2.15)	<0.001	1.46 (1.33-1.61)	<0.001	1.58 (1.37-1.82)	<0.001

<sup>#</sup> Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; CI= confidence interval; IRR= incidence rate ratio

**Supplementary Table 9:** Incidence rate ratios of consultations for respiratory tract infections (RTI) and wheeze between children in PT-Air and PT-O<sub>2</sub>

	Respiratory Tract Infections (RTI)				Wheeze			
	Unadjusted IRR (95% CI)	P value	Adjusted IRR <sup>#</sup> (95% CI)	P value	Unadjusted IRR (95% CI)	P value	Adjusted IRR <sup>#</sup> (95% CI)	P value
<b>Overall</b>	1.22 (1.15-1.3)	<0.001	1.21 (1.12-1.30)	<0.001	1.18 (0.99-1.41)	0.03	1.10 (0.86-1.42)	0.45
<b>Age</b>								
0-1	1.05 (0.94-1.18)	0.17	1.04 (0.93-1.16)	0.52	0.91 (0.65-1.24)	0.27	0.84 (0.61-1.15)	0.28
1-2	1.26 (1.12-1.40)	<0.001	1.24 (1.07-1.45)	0.004	1.22 (0.91-1.62)	0.08	1.16 (0.69-1.96)	0.57
2-3	1.23 (1.06-1.42)	0.003	1.24 (1.03-1.50)	0.02	1.75 (1.12-2.71)	0.01	1.81 (0.85-3.86)	0.12
3-4	1.37 (1.15-1.63)	<0.001	1.49 (1.17-1.90)	0.001	1.09 (0.49-2.25)	0.39	1.21 (0.59-2.48)	0.60
4-5	1.43 (1.15-1.77)	<0.001	1.65 (1.21-2.25)	0.002	1.24 (0.44-3.15)	0.31	1.16 (0.38-3.53)	0.80
<b>Sex</b>								
Male	1.28 (1.18-1.39)	<0.001	1.28 (1.16-1.42)	<0.001	1.11 (0.88-1.39)	0.18	0.96 (0.70-1.31)	0.79
Female	1.15 (1.05-1.26)	0.001	1.13 (1.01-1.27)	0.03	1.24 (0.92-1.65)	0.07	1.40 (0.90-2.19)	0.13
<b>IMD 2010 quintile</b>								
1 (least deprived)	1.12 (0.96-1.31)	0.07	1.17 (0.98-1.41)	0.09	1.24 (0.79-1.91)	0.16	1.53 (0.83-2.82)	0.17
2	1.15 (1.00-1.32)	0.02	1.12 (0.94-1.33)	0.20	1.37 (0.94-1.97)	0.04	1.03 (0.62-1.70)	0.91
3	1.49 (1.28-1.73)	<0.001	1.65 (1.37-1.98)	<0.001	1.16 (0.71-1.82)	0.26	1.15 (0.64-2.06)	0.64
4	1.18 (1.04-1.34)	0.01	1.14 (0.98-1.34)	0.01	1.77 (1.18-2.65)	0.002	1.68 (0.98-2.90)	0.06
5 (most deprived)	1.21 (1.07-1.38)	0.001	1.14 (0.98-1.33)	0.09	0.75 (0.50-1.11)	0.07	0.61 (0.33-1.10)	0.10
Missing	1.89 (0.49-10.70)	0.17	0.58 (0.04-9.14)	0.70	.	.	.	.
<b>Congenital anomalies</b>								
No CA	1.15 (1.06-1.23)	<0.001	1.16 (1.06-1.27)	0.001	1.08 (0.85-1.35)	0.26	1.15 (0.84-1.57)	0.40
Has CA	1.32 (1.17-1.48)	<0.001	1.33 (1.16-1.53)	<0.001	1.11 (0.81-1.52)	0.25	1.02 (0.69-1.52)	0.92

<sup>#</sup> Adjusted for age, sex, IMD 2010 quintile, congenital anomalies; CI= confidence interval; IRR= incidence rate ratio

**Supplementary Table 10:** Distribution of study population across two equal 8-year epochs

Epoch	Epoch 1 (1997-2005)	Epoch 2 (2006-2014)	
Term, n (%)	86,925 (99.2)	164,686 (99.4)	251,611
PT-Air, n (%)	496 (0.6)	721 (0.4)	1,217
PT-O <sub>2</sub> , n (%)	135 (0.2)	314 (0.2)	449
Total	87,556	165,721	253,277